Longleaf Partners, managed by Southeastern Asset Management, had a challenging 2025, returning 3.35% in the fourth quarter. The Fund underperformed due to no standout performers, unlike 35% of the S&P 500. The firm emphasizes building a real company portfolio for long-term benefit amidst market speculation. Check out the top five holdings for insights.

In the fourth quarter, Longleaf Partners Fund highlighted Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), a biotech company valued at $77.693 billion. Regeneron stock closed at $733.04 per share on January 16, 2026. The firm sees potential in Regeneron’s position in allergic diseases and oncology, with a low P/V ratio and strong pipeline value.

In the investor letter, Longleaf Partners Fund expressed optimism for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) despite early detractors. The firm praises Regeneron’s focus on allergic diseases and oncology, solid balance sheet, share repurchases, and pipeline value. The Fund sees Regeneron as a meaningful position with growth potential entering 2026.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) was held by 78 hedge fund portfolios in Q3, up from 73 in the previous quarter. While Regeneron has investment potential, Morgan Stanley sees greater upside in certain AI stocks. For those interested in undervalued AI stocks, check out their free report for opportunities in the current market climate.

Read more at Yahoo Finance: Should You Be Excited for Regeneron (REGN)?